Immuno-oncology
From the Journals
Patient-reported outcomes support first-line pembrolizumab for NSCLC
At week 18 in KEYNOTE-407, more patients in the pembrolizumab plus chemotherapy group reported improvements in health-related quality of life,...
From the Journals
Sequential CRT, immunotherapy nets high PFS in node-positive cervical cancer
More than four in five patients were alive and free of disease progression a year after receiving chemoradiotherapy followed by ipilimumab, and...
Conference Coverage
ASH preview: Key themes include tackling CAR T obstacles, sickle cell advances, VTE
New findings take aim at CAR T-cell therapy-related obstacles and highlight potential new paths forward.
Conference Coverage
Combo elicits lasting responses in metastatic melanoma
NATIONAL HARBOR, MD. – In a phase 1/2 trial of previously untreated advanced melanoma patients, the combination of bempegaldesleukin and nivolumab...
From the Journals
Atezolizumab/bevacizumab may offer benefit to patients with RCC
The combination performed better in renal cell carcinoma patients who were PD-L1 positive.
Conference Coverage
Neoantigen vaccine appears safe and active in NSCLC
NATIONAL HARBOR, MD. – The vaccine produced only grade 1 adverse events and yielded responses in 7 of 24 patients,...
Conference Coverage
Combo produces disappointing PFS, promising OS in metastatic colorectal cancer
NATIONAL HARBOR, MD. – Combination avelumab and cetuximab plus oxaliplatin, leucovorin, and 5-fluorouracil failed to meet the primary endpoint for...
Conference Coverage
Armored CAR T cells elicit responses in NHL patients
NATIONAL HARBOR, MD. – ICTCAR014, a dominant negative PD-1 armored CAR T-cell therapy, produced responses in 12 of 13 non-Hodgkin lymphoma...
Conference Coverage
Combo shows promise for checkpoint inhibitor-refractory urothelial carcinoma
NATIONAL HARBOR, MD – Combination sitravatinib and nivolumab produced responses in patients with checkpoint...
Conference Coverage
TLR9 agonist may overcome resistance to anti–PD-1 therapy in melanoma
NATIONAL HARBOR, MD. – CMP-001 plus pembrolizumab produced durable responses in patients who had progressed on prior...
Conference Coverage
Molecule exhibits activity in heavily pretreated, HER2-positive solid tumors
NATIONAL HARBOR, MD – In a phase 1 trial of 18 evaluable patients, PRS-343, a 4-1BB/HER2 bispecific molecule,...